Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Non-Current Deffered Revenue: 2024

Historic Non-Current Deffered Revenue for Prime Medicine (PRME) over the last 1 years, with Dec 2024 value amounting to $63.2 million.

  • Prime Medicine's Non-Current Deffered Revenue fell 4.61% to $59.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.8 million, marking a year-over-year decrease of 4.61%. This contributed to the annual value of $63.2 million for FY2024, which is N/A change from last year.
  • As of FY2024, Prime Medicine's Non-Current Deffered Revenue stood at $63.2 million.
  • In the past 5 years, Prime Medicine's Non-Current Deffered Revenue ranged from a high of $63.2 million in FY2024 and a low of $63.2 million during FY2024.
  • Moreover, its 1-year median value for Non-Current Deffered Revenue was $63.2 million (2024), whereas its average is $63.2 million.